| Business Summary | | Entropin,
Inc.
is
a
development-stage
pharmaceutical
company
that
has
developed
Esterom,
a
topical
formulation
for
the
treatment
of
conditions
involving
impaired
range
of
motion,
which
often
accompanies
injuries
and
disorders
of
the
shoulder
and
lower
back,
as
well
as
other
conditions
affecting
body
joints.
Esterom
is
derived
from
a
process
involving
the
chemical
breakdown
of
cocaine
into
new
and
different
molecules,
three
of
which
have
been
patented
by
the
Company.
Entropin
has
completed
four
preclinical
animal
studies
and
Phase
I
and
Phase
II
human
clinical
trials
for
Esterom.
These
trials
indicated
that
Esterom
was
well
tolerated
and
did
not
appear
to
have
any
potential
for
addiction
or
abuse. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Entropin,
Inc.
is
a
bio-pharmaceutical
company
developing
a
patented
topical
medicinal
preparation
effective
in
the
treatment
of
impaired
range
of
motion
associated
with
acute
lower
back
sprain
and
painful
shoulder.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
applicable
to
Common
fell
32%
to
$1.8
million.
Lower
loss
reflects
reductions
in
general
and
administrative
expenses
and
increased
investment
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Higgins Bailey, 70 Chairman | -- | Thomas Tachovsky, 54 Pres,
CEO, Director | $220K | Patricia Kriss, 50 VP
of Fin. and Admin., CFO | 100K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|